Multiple Etiology Dementias: Determine impact of cognitive screening in midlife (Milestone 9.N)
To Be Initiated
Timeline Start - End
2022 - 2028Research Implementation Area
BiomarkersAD-Related Dementias Focus
Evaluate the benefits, burdens, and harms of screening for cognitive impairment in older adults in the absence of a patient, care partner or clinician report of cognitive, behavioral, or functional changes.
Success Criteria
- At least one real-world clinical practice study to determine the benefits, burdens, and harms of screening for cognitive impairment including dementia in older adults. This trial is to be powered to answer the question in at least two populations that experience health disparities.
Summary of Key Accomplishments
This milestone has yet to be initiated. Accomplishments are forthcoming.
The key accomplishments summary is current as of July 2022.
Accomplishments/Implementation Activities
Funding Initiatives
Research Programs and Resources
Relevant Recommendations
- ADRD Summit 2016: Multiple Etiology Dementias (MED) Focus Area 3: Determining the Role for Screening for Cognitive Dysfunction, Milestone 6
- ADRD Summit 2022: Multiple Etiology Dementias (MED) Milestone 2, Priority 4